The subsequent emergence of an on-target MET resistance mutation and loss of MET amplification highlights the temporal evolution of multi-faceted MET signaling axis activation and complex overall molecular landscape longitudinally as tumor cells acquire resistance to sequential targeted therapies. The gene discussed is MET; the disease is neoplasm.